Posted by Michael Wonder on 01 Mar 2023
Reata Pharmaceuticals announces FDA approval of Skyclarys (omavaloxolone), the first and only drug indicated for patients with Friedreich’s ataxia
28 February 2023 - Rare paediatric disease priority review voucher granted.
Reata Pharmaceuticals announced that the US FDA has approved Skyclarys (omaveloxolone) for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.
